<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03453359</url>
  </required_header>
  <id_info>
    <org_study_id>01/18</org_study_id>
    <nct_id>NCT03453359</nct_id>
  </id_info>
  <brief_title>Bispectral Index Monitoring of Sedation in Spontaneous Ventilation. Clinical Trial in Scheduled Colonoscopies</brief_title>
  <acronym>BIS</acronym>
  <official_title>Bispectral Index Monitoring of Sedation in Spontaneous Ventilation. Clinical Trial in Scheduled Colonoscopies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Galdakao-Usansolo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Galdakao-Usansolo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the monitoring of anesthetic depth in colonoscopies using
      the bispectral index monitor versus conventional monitoring as a guide for sedation, allowing
      to offer the best care in terms of patient safety. The investigators will choose non-obese
      adult patients without many pathologies and with intact neurological capacity. They must
      voluntarily participate in the study and sign the informed consent designed specifically for
      the study. The main hypothesis is that the percentage of optimal sedation in the group of
      patients guided by the monitoring of the bispectral index will be 20% higher than in the
      group guided in a conventional manner. The investigators expect significant differences in
      the incidence of complications, total dose of drugs and need for rescue medication. There
      will be no significant difference in the satisfaction with the colonoscopy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized double-blind clinical trial in patients undergoing scheduled colonoscopies in
      endoscopy rooms of the Galdakao-Us치nsolo Hospital. The investigators will compare the
      percentage of optimal sedation (defined as bispectral index -BIS- parameter between 65 and 85
      or score on the Ramsay scale 2 or 3) as well as the need for rescue medication and incidence
      of complications among the experimental group in which sedation is guided by BIS and the
      control in which the anesthesiologist is blind to the result of the BIS. The investigators
      hope that the use of BIS decreases the chances throughout the colonoscopy in which it is
      necessary to increase the level of sedation.

      The BIS is the parameter of anesthetic depth monitoring most used today. Its use was approved
      by the Food and Drug Administration (FDA) in 1996 as an aid to control the effects of certain
      anesthetic agents. It is validated in the operating room (Recommendation grade A), but not
      outside it due to lack of conclusive studies.

      180 patients are needed to obtain statistically significant differences between both groups.
      Qualitative variables are expressed in the form of frequencies and percentages and continuous
      variables in the form of means and standard deviations. Comparisons of percentages will be
      made by the Chi square test (or Exact Fisher's test, when the expected frequencies are less
      than 5) and the difference of means in the continuous variables by the t test as well as by
      the Wilcoxon nonparametric test if the distribution of the variable requires it. The degree
      of agreement between the BIS and Ramsay scale will be made through the weighted Kappa test.
      Statistical significance will be assumed when p &lt;0.05. All statistical analyzes will be
      carried out using SAS V9.4. (SAS institute, Inc., Carey, NC).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>We compared the results of two groups of patients. Experimental group, in which sedation is adjusted using as main parameters the information obtained by the bispectral index monitor. Control Group, with sedation based on subjective monitoring using the Ramsay scale as a reference.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Patients will be randomly assigned to one of the two study groups. The anesthesiologist who records the information knows which group they belong to, according to a randomization table provided in collaboration with the Research Unit, but the patients do not know it.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Level of sedation</measure>
    <time_frame>1 year.</time_frame>
    <description>Sedation measured by Bispectral Index compared with Ramsay sedation score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications related to sedation.</measure>
    <time_frame>1 year.</time_frame>
    <description>Complications related to sedation will be measured: hypotension, bradycardia, apnea, hypercapnia and low oxygen saturation mainly. This will be evaluated for all patients. The medications or maneuvers that are necessary to correct these complications will also be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The need for rescue medication.</measure>
    <time_frame>1 year.</time_frame>
    <description>The investigators will note if it is necessary to administer additional medication to perform the test. They will indicate when and the number of times it is done.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of satisfaction with the colonoscopy.</measure>
    <time_frame>1 year.</time_frame>
    <description>The investigators will distribute a satisfaction questionnaire to all patients after the colonoscopy to find out their opinion about the quality of sedation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Colonoscopy</condition>
  <arm_group>
    <arm_group_label>BIS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group of patients (90) in whom sedation is adjusted using as main parameters the information obtained by the BIS sedation monitor (BIS VISTA, Aspect Medical Systems, USA).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramsay</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group of patients (90) in whom sedation is based on subjective monitoring of the level of sedation, using the Ramsay scale as a reference.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BIS monitor</intervention_name>
    <description>The investigators will place on the forehead of all patients the sensor BIS quatroTM, that connects with this monitor, and they will guide sedation and will record the values obtained.</description>
    <arm_group_label>BIS</arm_group_label>
    <other_name>BIS VISTA; Aspect Medical Systems, USA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ramsay scale</intervention_name>
    <description>In this group, sedation is guided by the Ramsay monitoring scale. The investigators will talk with the patients and will determine the corresponding level of sedation.</description>
    <arm_group_label>Ramsay</arm_group_label>
    <other_name>Conventional monitoring</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication of complete colonoscopy on a scheduled basis.

          -  Classification of physical status ASA I, II and III, with the exception of patients
             with moderate to severe kidney and / or liver disease.

          -  Intermittent or persistent mild asthma. It implies the absence of daily symptoms and
             FEV1&gt; 80% (GINA 2004).

          -  Body Mass Index (BMI) less than 35 kg / m2, and greater than 18 kg/m2.

          -  Intact neurological capacity.

          -  Acceptance to participate in the study after the contribution of written informed
             consent.

        Exclusion Criteria:

          -  ASA IV.

          -  BMI greater than 35 kg / m2, and less than 18 kg/m2.

          -  Refusal to participate in the study.

          -  Allergy to any of the medications used in sedation, or its components.

          -  Known mental or neurological disease.

          -  Renal and / or moderate to severe Hepatic insufficiency.

          -  Chronic Obstructive Pulmonary Disease (COPD) or Obstructive Sleep Apnea.

          -  Chronic opiate users.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iratxe Gonzalez Mendibil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Galdakao-Usansolo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Iratxe Gonzalez Mendibil, MD</last_name>
    <phone>944007000</phone>
    <phone_ext>7030</phone_ext>
    <email>iratxe.gonzalezmendibil@osakidetza.eus</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eduardo Garcia Pascual, MD</last_name>
    <phone>944007000</phone>
    <phone_ext>7030</phone_ext>
    <email>eduardo.garciapascual@osakidetza.eus</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Galdakao-Usansolo</name>
      <address>
        <city>Galdakao</city>
        <state>Vizcaya</state>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iratxe Gonz치lez Mendibil, MD</last_name>
      <phone>944007000</phone>
      <phone_ext>7030</phone_ext>
      <email>iratxe.gonzalezmendibil@osakidetza.eus</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Thomson A, Andrew G, Jones DB. Optimal sedation for gastrointestinal endoscopy: review and recommendations. J Gastroenterol Hepatol. 2010 Mar;25(3):469-78. doi: 10.1111/j.1440-1746.2009.06174.x. Review.</citation>
    <PMID>20370725</PMID>
  </reference>
  <reference>
    <citation>Dumonceau JM, Riphaus A, Schreiber F, Vilmann P, Beilenhoff U, Aparicio JR, Vargo JJ, Manolaraki M, Wientjes C, R치cz I, Hassan C, Paspatis G. Non-anesthesiologist administration of propofol for gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy, European Society of Gastroenterology and Endoscopy Nurses and Associates Guideline--Updated June 2015. Endoscopy. 2015 Dec;47(12):1175-89. doi: 10.1055/s-0034-1393414. Epub 2015 Nov 12.</citation>
    <PMID>26561915</PMID>
  </reference>
  <reference>
    <citation>Park WY, Shin YS, Lee SK, Kim SY, Lee TK, Choi YS. Bispectral index monitoring during anesthesiologist-directed propofol and remifentanil sedation for endoscopic submucosal dissection: a prospective randomized controlled trial. Yonsei Med J. 2014 Sep;55(5):1421-9. doi: 10.3349/ymj.2014.55.5.1421.</citation>
    <PMID>25048506</PMID>
  </reference>
  <reference>
    <citation>Hong MJ, Sung IK, Lee SP, Cheon BK, Kang H, Kim TY. Randomized comparison of recovery time after use of remifentanil alone versus midazolam and meperidine for colonoscopy anesthesia. Dig Endosc. 2015 Jan;27(1):113-20. doi: 10.1111/den.12383. Epub 2014 Nov 11.</citation>
    <PMID>25251893</PMID>
  </reference>
  <reference>
    <citation>Lera dos Santos ME, Maluf-Filho F, Chaves DM, Matuguma SE, Ide E, Luz Gde O, de Souza TF, Pessorrusso FC, de Moura EG, Sakai P. Deep sedation during gastrointestinal endoscopy: propofol-fentanyl and midazolam-fentanyl regimens. World J Gastroenterol. 2013 Jun 14;19(22):3439-46. doi: 10.3748/wjg.v19.i22.3439.</citation>
    <PMID>23801836</PMID>
  </reference>
  <reference>
    <citation>Yu YH, Han DS, Kim HS, Kim EK, Eun CS, Yoo KS, Shin WJ, Ryu S. Efficacy of bispectral index monitoring during balanced propofol sedation for colonoscopy: a prospective, randomized controlled trial. Dig Dis Sci. 2013 Dec;58(12):3576-83. doi: 10.1007/s10620-013-2833-4. Epub 2013 Aug 28.</citation>
    <PMID>23982208</PMID>
  </reference>
  <reference>
    <citation>Sasaki T, Tanabe S, Azuma M, Sato A, Naruke A, Ishido K, Katada C, Higuchi K, Koizumi W. Propofol sedation with bispectral index monitoring is useful for endoscopic submucosal dissection: a randomized prospective phase II clinical trial. Endoscopy. 2012 Jun;44(6):584-9. doi: 10.1055/s-0032-1306776. Epub 2012 May 25.</citation>
    <PMID>22638779</PMID>
  </reference>
  <reference>
    <citation>Imagawa A, Fujiki S, Kawahara Y, Matsushita H, Ota S, Tomoda T, Morito Y, Sakakihara I, Fujimoto T, Taira A, Tsugeno H, Kawano S, Yagi S, Takenaka R. Satisfaction with bispectral index monitoring of propofol-mediated sedation during endoscopic submucosal dissection: a prospective, randomized study. Endoscopy. 2008 Nov;40(11):905-9.</citation>
    <PMID>19023932</PMID>
  </reference>
  <reference>
    <citation>Qadeer MA, Vargo JJ, Patel S, Dumot JA, Lopez AR, Trolli PA, Conwell DL, Stevens T, Zuccaro G Jr. Bispectral index monitoring of conscious sedation with the combination of meperidine and midazolam during endoscopy. Clin Gastroenterol Hepatol. 2008 Jan;6(1):102-8. Epub 2007 Dec 11.</citation>
    <PMID>18065278</PMID>
  </reference>
  <reference>
    <citation>Liu SS. Effects of Bispectral Index monitoring on ambulatory anesthesia: a meta-analysis of randomized controlled trials and a cost analysis. Anesthesiology. 2004 Aug;101(2):311-5.</citation>
    <PMID>15277912</PMID>
  </reference>
  <reference>
    <citation>Bower AL, Ripepi A, Dilger J, Boparai N, Brody FJ, Ponsky JL. Bispectral index monitoring of sedation during endoscopy. Gastrointest Endosc. 2000 Aug;52(2):192-6.</citation>
    <PMID>10922090</PMID>
  </reference>
  <reference>
    <citation>Oliveira CR, Bernardo WM, Nunes VM. Benefit of general anesthesia monitored by bispectral index compared with monitoring guided only by clinical parameters. Systematic review and meta-analysis. Braz J Anesthesiol. 2017 Jan - Feb;67(1):72-84. doi: 10.1016/j.bjane.2015.09.001. Epub 2016 Apr 14. Review.</citation>
    <PMID>28017174</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2018</study_first_submitted>
  <study_first_submitted_qc>March 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2018</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Galdakao-Usansolo</investigator_affiliation>
    <investigator_full_name>Iratxe Gonz치lez Mendibil</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>deep sedation</keyword>
  <keyword>spontaneous ventilation</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The investigators have a randomization table to assign the intervention of each patient. The investigators will record anthropometric data and the parameters resulting from the monitoring. These data will be available to collaborating investigators and subsequently to a member of the Research Unit who will record this information in a database that will be analyzed to obtain results.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

